All these findings indicate that (1) genetic variations in TREK-1 may identify individuals at risk for depression treatment resistance and (2) a search of selective blockers of TREK-1, hitherto not available, might potentially lead to a new generation of antidepressants. This evidence concerns the gene KCNK2 and major depressive disorder.